

Product Datasheet

GNF-5

Catalog No. **BP-02121** · CAS **778277-15-9** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-02**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Bcr-Abl	Research area Cancer
--------------------------	--------------------------------

Molecular formula **C₂₀H₁₇F₃N₄O₃**

Molecular weight **418.3692**

STRUCTURE



DESCRIPTION

GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC₅₀ value of 0.22 μM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer .

BIOLOGICAL ACTIVITY

In Vitro

GNF-5 has inhibition of wild-type Abl with an IC₅₀ value of 0.22 μM but no inhibition for myristate site mutant E505K (IC₅₀ > 10 μM).

In Vivo

GNF-5 (5 mg/kg iv. or 20 mg/kg oral) has suitable pharmacokinetic parameters.

GNF-5 (oral, 50 or 100 mg/kg, twice daily, for 7 days) shows efficacious in vivo but can observe relapses.

GNF-5 (75 mg/kg, b.i.d) inhibits T315I Bcr-Abl combination with nilotinib in vivo.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Zhang J, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6.

[2]. Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.